VAXXINITY INC-A (VAXX)

US92244V1044 - Common Stock

0.7147  +0.02 (+3.58%)

News Image
2 hours ago - Vaxxinity, Inc.

Vaxxinity to Present Clinical Data at the Annual Academy of Neurology 2024 Annual Meeting

Presentation will address the Company’s clinical data in Parkinson’s disease

News Image
2 hours ago - Vaxxinity, Inc.

Vaxxinity to Present Clinical Data at the Annual Academy of Neurology 2024 Annual Meeting

Presentation will address the Company’s clinical data in Parkinson’s disease

News Image
13 hours ago - InvestorPlace

VAXX Stock Earnings: Vaxxinity Beats EPS for Q4 2023

VAXX stock results show that Vaxxinity beat analyst estimates for earnings per share the fourth quarter of 2023.

News Image
13 hours ago - BusinessInsider

VAXX Stock Earnings: Vaxxinity Beats EPS for Q4 2023

InvestorPlace - Stock Market News, Stock Advice & Trading Tips Vaxxinity (NASDAQ:VAXX) just reported results for the fourth quarter of 2023.Va...

News Image
19 hours ago - Vaxxinity, Inc.

Vaxxinity Reports Fourth Quarter and Full-Year 2023 Financial Results and Provides Corporate Updates

CAPE CANAVERAL, Fla., March 27, 2024 (GLOBE NEWSWIRE) -- Vaxxinity, Inc. (Nasdaq: VAXX), a U.S. company pioneering the development of a new class of...

News Image
3 days ago - Chartmill

Discover the top movers in Monday's after-hours session and stay informed about the post-market dynamics.

After the closing bell on Monday, let's take a glimpse of the US markets and explore the top gainers and losers in today's after-hours session.

News Image
21 days ago - Vaxxinity, Inc.

Vaxxinity Announces Positive Target Engagement Data from Phase 1 Clinical Trial for Parkinson’s Disease at AD/PD™ 2024

UB-312 is first immunotherapy to show reduction of pathological alpha-synuclein in cerebrospinal fluid of Parkinson’s patients

News Image
21 days ago - Vaxxinity, Inc.

Vaxxinity Announces Positive Target Engagement Data from Phase 1 Clinical Trial for Parkinson’s Disease at AD/PD™ 2024

UB-312 is first immunotherapy to show reduction of pathological alpha-synuclein in cerebrospinal fluid of Parkinson’s patients...

News Image
a month ago - Vaxxinity, Inc.

Vaxxinity’s Cholesterol Vaccine Candidate Successfully Lowers LDL-C: Preclinical Data Published

Preclinical data published in the Journal of Lipid Research indicate VXX-401 is well-tolerated, with no safety signals observed, and robustly reduces LDL-C...

News Image
a month ago - Vaxxinity, Inc.

Vaxxinity to Present Clinical and Preclinical Pipeline Data at AD/PD 2024

CAPE CANAVERAL, Fla., Feb. 13, 2024 (GLOBE NEWSWIRE) -- Vaxxinity, Inc. (Nasdaq: VAXX), a U.S. company pioneering the development of a new class of...

News Image
2 months ago - Vaxxinity, Inc.

Vaxxinity Announces Research Collaboration on Active Immunotherapies for Neurodegenerative Diseases with University of Florida

CAPE CANAVERAL, Fla., Jan. 30, 2024 (GLOBE NEWSWIRE) -- Vaxxinity, Inc. (Nasdaq: VAXX), a U.S. company pioneering the development of a new class of...

News Image
2 months ago - Vaxxinity, Inc.

Vaxxinity Announces Collaboration on Space Medicine Research with University of Central Florida

CAPE CANAVERAL, Fla., Jan. 18, 2024 (GLOBE NEWSWIRE) -- Vaxxinity, Inc. (Nasdaq: VAXX), a U.S. company pioneering the development of a new class of...

News Image
3 months ago - Vaxxinity, Inc.

Vaxxinity to Present at the 2024 J.P. Morgan Healthcare Conference

CAPE CANAVERAL, Fla., Jan. 03, 2024 (GLOBE NEWSWIRE) -- Vaxxinity, Inc. (Nasdaq: VAXX), a U.S. company pioneering the development of a new class of...

News Image
4 months ago - Investor's Business Daily

Quest For Alzheimer's Cure: Big Biotech Breakthroughs, But The Race Is Just Beginning

Biotech companies are edging closer to finding the answers behind Alzheimer's disease.

News Image
5 months ago - Vaxxinity, Inc.

Vaxxinity to Present at Upcoming November Medical and Investor Conferences

CAPE CANAVERAL, Fla., Nov. 13, 2023 (GLOBE NEWSWIRE) -- Vaxxinity, Inc. (Nasdaq: VAXX), a U.S. company pioneering the development of a new class of...

News Image
5 months ago - Vaxxinity, Inc.

Vaxxinity Reports Third Quarter 2023 Financial Results and Provides Corporate Update

CAPE CANAVERAL, Fla., Nov. 08, 2023 (GLOBE NEWSWIRE) -- Vaxxinity, Inc. (Nasdaq: VAXX), a U.S. company pioneering the development of a new class of...

News Image
7 months ago - Vaxxinity, Inc.

Vaxxinity to Present at Upcoming Investor Conferences in September

CAPE CANAVERAL, Fla., Aug. 29, 2023 (GLOBE NEWSWIRE) -- Vaxxinity, Inc. (Nasdaq: VAXX), a U.S. company pioneering the development of a new class of...

News Image
8 months ago - Seeking Alpha

(NASDAQ:VAXX)

Vaxxinity press release (VAXX): Q2 GAAP EPS of -$0.11.As of June 30, 2023, Vaxxinity had $56.1 million of highly liquid assets, including $37.1 million of cash and cash equivalents,...

News Image
8 months ago - Vaxxinity, Inc.

Vaxxinity Announces Publication of UB-311 Safety, Tolerability, Immunogenicity, and Clinical Efficacy Data from Phase 2a Trial in Alzheimer’s Disease

Phase 2a data published in The Lancet’s eBioMedicine supports further development of UB-311 The paper concludes that UB-311 is the most advanced active...

News Image
8 months ago - Vaxxinity, Inc.

Vaxxinity Reports Second Quarter 2023 Financial Results and Provides Corporate Update

CAPE CANAVERAL, Fla., Aug. 09, 2023 (GLOBE NEWSWIRE) -- Vaxxinity, Inc. (Nasdaq: VAXX), a U.S. company pioneering the development of a new class of medicines, today reported financial results for the second quarter ended June 30, 2023, and provided a corporate update.

News Image
8 months ago - Vaxxinity, Inc.

Vaxxinity Appoints Peter Powchik, M.D., to Executive Vice President, Global Scientific Director

Appointment adds Dr. Powchik’s experience in the development of marketed immunotherapeutics to Vaxxinity’s leadership team